12.49 USD
+0.01 (+0.08%)
Taking everything into account, CDMO scores 2 out of 10 in our fundamental rating. CDMO was compared to 535 industry peers in the Biotechnology industry. Both the profitability and financial health of CDMO have multiple concerns. CDMO is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year CDMO has reported negative net income.
In the past year CDMO had a positive cash flow from operations.
In multiple years CDMO reported negative net income over the last 5 years.
CDMO had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
CDMO's Return On Assets of -47.00% is in line compared to the rest of the industry. CDMO outperforms 48.85% of its industry peers.
CDMO has a Return On Equity of -339.34%. This is in the lower half of the industry: CDMO underperforms 76.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -47% | ||
| ROE | -339.34% | ||
| ROIC | N/A |
ROA(3y)-3.99%
ROA(5y)-4.97%
ROE(3y)-52.56%
ROE(5y)-37.94%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 7.68%, CDMO is in the better half of the industry, outperforming 73.81% of the companies in the same industry.
CDMO's Gross Margin has declined in the last couple of years.
CDMO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 7.68% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-44.47%
GM growth 5Y-17.19%
2. Health
2.1 Basic Checks
CDMO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CDMO has more shares outstanding
The number of shares outstanding for CDMO has been increased compared to 5 years ago.
CDMO has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -0.51, we must say that CDMO is in the distress zone and has some risk of bankruptcy.
With a decent Altman-Z score value of -0.51, CDMO is doing good in the industry, outperforming 61.95% of the companies in the same industry.
A Debt/Equity ratio of 3.58 is on the high side and indicates that CDMO has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 3.58, CDMO is doing worse than 84.07% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.58 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.51 |
ROIC/WACCN/A
WACC8.72%
2.3 Liquidity
A Current Ratio of 1.30 indicates that CDMO should not have too much problems paying its short term obligations.
The Current ratio of CDMO (1.30) is worse than 83.89% of its industry peers.
A Quick Ratio of 0.92 indicates that CDMO may have some problems paying its short term obligations.
The Quick ratio of CDMO (0.92) is worse than 87.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.3 | ||
| Quick Ratio | 0.92 |
3. Growth
3.1 Past
CDMO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1305.88%.
CDMO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -15.80%.
Measured over the past years, CDMO shows a very strong growth in Revenue. The Revenue has been growing by 21.15% on average per year.
EPS 1Y (TTM)-1305.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-80%
Revenue 1Y (TTM)-15.8%
Revenue growth 3Y13.42%
Revenue growth 5Y21.15%
Sales Q2Q%31.84%
3.2 Future
The Earnings Per Share is expected to grow by 27.71% on average over the next years. This is a very strong growth
Based on estimates for the next years, CDMO will show a very strong growth in Revenue. The Revenue will grow by 22.14% on average per year.
EPS Next Y86.15%
EPS Next 2Y38.79%
EPS Next 3Y27.71%
EPS Next 5YN/A
Revenue Next Year17.28%
Revenue Next 2Y17.02%
Revenue Next 3Y18.3%
Revenue Next 5Y22.14%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
CDMO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CDMO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CDMO's earnings are expected to grow with 27.71% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.79%
EPS Next 3Y27.71%
5. Dividend
5.1 Amount
CDMO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:CDMO (2/4/2025, 8:00:02 PM)
12.49
+0.01 (+0.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners105.25%
Inst Owner Change-71.45%
Ins Owners0.95%
Ins Owner Change0%
Market Cap801.11M
Revenue(TTM)150.44M
Net Income(TTM)-152.05M
Analysts74.55
Price Target12.75 (2.08%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-92.85%
Min EPS beat(2)-125.28%
Max EPS beat(2)-60.43%
EPS beat(4)0
Avg EPS beat(4)-1306.42%
Min EPS beat(4)-4971.9%
Max EPS beat(4)-60.43%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-3.13%
Min Revenue beat(2)-3.38%
Max Revenue beat(2)-2.89%
Revenue beat(4)0
Avg Revenue beat(4)-1.8%
Min Revenue beat(4)-3.38%
Max Revenue beat(4)-0.02%
Revenue beat(8)3
Avg Revenue beat(8)-3.35%
Revenue beat(12)7
Avg Revenue beat(12)0.75%
Revenue beat(16)11
Avg Revenue beat(16)3.84%
PT rev (1m)0%
PT rev (3m)-7.41%
EPS NQ rev (1m)-9.09%
EPS NQ rev (3m)-50%
EPS NY rev (1m)-1.69%
EPS NY rev (3m)-1.69%
Revenue NQ rev (1m)-2.16%
Revenue NQ rev (3m)0.42%
Revenue NY rev (1m)-0.11%
Revenue NY rev (3m)-0.34%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 5.32 | ||
| P/FCF | N/A | ||
| P/OCF | 152.36 | ||
| P/B | 17.88 | ||
| P/tB | 17.88 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.39
EYN/A
EPS(NY)-0.16
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)0.08
OCFY0.66%
SpS2.35
BVpS0.7
TBVpS0.7
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -47% | ||
| ROE | -339.34% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 7.68% | ||
| FCFM | N/A |
ROA(3y)-3.99%
ROA(5y)-4.97%
ROE(3y)-52.56%
ROE(5y)-37.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-44.47%
GM growth 5Y-17.19%
F-Score4
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.58 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 119.78% | ||
| Cap/Sales | 9.93% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.3 | ||
| Quick Ratio | 0.92 | ||
| Altman-Z | -0.51 |
F-Score4
WACC8.72%
ROIC/WACCN/A
Cap/Depr(3y)874.1%
Cap/Depr(5y)606.28%
Cap/Sales(3y)40.63%
Cap/Sales(5y)27.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1305.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-80%
EPS Next Y86.15%
EPS Next 2Y38.79%
EPS Next 3Y27.71%
EPS Next 5YN/A
Revenue 1Y (TTM)-15.8%
Revenue growth 3Y13.42%
Revenue growth 5Y21.15%
Sales Q2Q%31.84%
Revenue Next Year17.28%
Revenue Next 2Y17.02%
Revenue Next 3Y18.3%
Revenue Next 5Y22.14%
EBIT growth 1Y-69.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year176.36%
EBIT Next 3Y71.06%
EBIT Next 5YN/A
FCF growth 1Y89.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y277.64%
OCF growth 3Y-29.44%
OCF growth 5YN/A
AVID BIOSERVICES INC / CDMO FAQ
What is the ChartMill fundamental rating of AVID BIOSERVICES INC (CDMO) stock?
ChartMill assigns a fundamental rating of 2 / 10 to CDMO.
Can you provide the valuation status for AVID BIOSERVICES INC?
ChartMill assigns a valuation rating of 1 / 10 to AVID BIOSERVICES INC (CDMO). This can be considered as Overvalued.
Can you provide the profitability details for AVID BIOSERVICES INC?
AVID BIOSERVICES INC (CDMO) has a profitability rating of 2 / 10.
Can you provide the financial health for CDMO stock?
The financial health rating of AVID BIOSERVICES INC (CDMO) is 1 / 10.
What is the expected EPS growth for AVID BIOSERVICES INC (CDMO) stock?
The Earnings per Share (EPS) of AVID BIOSERVICES INC (CDMO) is expected to grow by 86.15% in the next year.